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SUMMARY
Herceptin (trastuzumab) is the backbone of HER2-directed breast cancer therapy and benefits patients in
both the adjuvant and metastatic settings. Here, we describe a mechanism of action for trastuzumab
whereby antibody treatment disrupts ligand-independent HER2/HER3 interactions in HER2-amplified cells.
The kinetics of dissociation parallels HER3 dephosphorylation and uncoupling from PI3K activity, leading to
downregulation of proximal and distal AKT signaling, and correlates with the antiproliferative effects of tras-
tuzumab. A selective and potent PI3K inhibitor, GDC-0941, is highly efficacious both in combination with tras-
tuzumab and in the treatment of trastuzumab-resistant cells and tumors.INTRODUCTION
Herceptin (trastuzumab) was initially approved for the treatment
of women with metastatic breast cancer overexpressing HER2/
ErbB2. The randomized clinical trial that led to this approval
was conducted in combination with standard cytotoxic chemo-
therapy (Slamon et al., 2001). In addition, two single-agent,
single-arm studies were also conducted in metastatic breast
cancer patients, and these studies demonstrated that trastuzu-
mab alone had a finite and measurable response rate (Cobleigh
et al., 1999; Vogel et al., 2002). Long-term therapeutic benefit is
also recognized in the adjuvant setting. For early-stage, HER2-
positive breast cancer patients, trastuzumab therapy after
chemotherapy offers significant benefit (Smith et al., 2007).
Trastuzumab is thought to manifest its mechanism of action in
multiple ways. As a humanized IgG1, it binds to Fcg receptor III
(RIII) and is a potent mediator of antibody-dependent, cell-medi-
ated cytotoxicity (ADCC). Evidence for the importance of
Fc-FcgRIII involvement in the mechanism of action of trastuzu-
mab is provided by Clynes et al. (2000), who assessed trastuzu-
mab response in tumor models deficient in FcgRIII function. In
addition to engaging immune effector cells, numerous investiga-
tions suggest that trastuzumab also inhibits tumor cell signalingor shows partial agonist activities (Sarup et al., 1991). The
biochemical nature of these properties is confusing and contro-
versial. Initially, it was thought that engagement of HER2 by tras-
tuzumab led to an increase in HER2 endocytosis or degradation
rate (Hudziak et al., 1989). Careful analysis of HER2 endocytosis
led to the conclusion that the monoclonal antibodies do not
affect HER2 internalization or endocytic rates (Austin et al.,
2004; Hommelgaard et al., 2004). Additionally, trastuzumab is
not effective in blocking dimerization of HER2 with ligand-acti-
vated EGFR or HER3 (Agus et al., 2002). Nevertheless, trastuzu-
mab treatment does result in G1-S cell cycle growth arrest that
does not lead to apoptosis (Lewis et al., 1996). Several reports
suggest that the cytostatic effect of trastuzumab correlates
with a downregulation of AKT activity, which ultimately leads to
an increase in the CDK2 inhibitor p27 (Lane et al., 2000; Lee
et al., 2001; Yakes et al., 2002). Furthermore, trastuzumab is
reported to have either no effect on HER2 activation status or
to cause a rapid increase or decrease of HER2 phosphorylation
(Lane et al., 2000; Nagata et al., 2004; Sarup et al., 1991).
A number of studies suggest that the transformation potential
of HER2 is augmented by coexpression with HER3 (Cohen et al.,
1996; Zhang et al., 1996). Interfering with or ablating HER3
expression or interaction with HER2 resulted in antiproliferativeSIGNIFICANCE
This study characterizes a mechanism of action for trastuzumab whereby trastuzumab disrupts the constitutively signaling
ligand-independent HER2/HER3/PI3K complex. The findings presented suggest that a combination of trastuzumab and the
PI3K inhibitor GDC-0941 warrants clinical evaluation in patients who have not been treated with a HER2-directed therapy in
themetastatic setting.Moreover, patients who progress on trastuzumab or lapatinib (a HER2-directed tyrosine kinase inhib-
itor) may derive benefit from additional therapy that includes the PI3K inhibitor GDC-0941.Cancer Cell 15, 429–440, May 5, 2009 ª2009 Elsevier Inc. 429
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Trastuzumab Disrupts the HER2/HER3/PI3K ComplexFigure 1. Trastuzumab-Induced Inhibition of
Proliferation Correlates with Inhibition of the
HER3/PI3K/AKT Pathway
(A) Pre-established BT474-M1 tumor xenografts were
treated with 20 mg/kg trastuzumab or control antibody.
Tumors were harvested after 48 hr, homogenized, and
analyzed for pHER3 (Tyr1289) and total HER3 by western
blot. pAKT (Ser473) and total AKT were analyzed by using
ELISA. The statistical significance was determined by
using Dunnett’s test.
(B) SKBR-3 cells were treated with 10 mg/ml trastuzumab
for indicated times. pHER3 (Tyr1289), pAKT (Ser473), and
pPRAS40 (Thr246) were analyzed by using western blot or
ELISA (pAKT). See Figure S1A for original western blots.
(C) SKBR-3 cells were treated with 10 mg/ml trastuzumab
for indicated times or with heregulin (HRG) for 15 min. The
p85 subunit of PI3K was detected from HER3 immunopre-
cipitates by western blot. pHER3 (Tyr1289) was blotted
directly from the lysates.
(D) SKBR-3 and BT474-M1 cells were treated with
10 mg/ml trastuzumab for 96 hr. pHER3 was analyzed by
HER3 immunoprecipitation, followed by detection with
HRP-conjugated p-Tyr antibody. pAKT (Ser473) was
analyzed by using ELISA.
(E) HER2-overexpressing cancer cells and MCF-7 cells
were treated with or without 10 mg/ml trastuzumab for
2 hr, lysed, and subjected to pAKT ELISA (Ser473). Cell
lines were grouped as pAKT responsive (red columns)
and nonresponsive (black columns) according to the level
of pAKT inhibition by trastuzumab. 25% inhibition was
used as a cutoff for the response.
(F) Trastuzumab dose response of pAKT-responsive
(SKBR-3) and -nonresponsive (KPL-4) cells. pAKT
(Ser473) was analyzed by ELISA after 2 hr of treatment.
Proliferation was analyzed after 6 days of treatment.
(G) Trastuzumab dose response (see [E] for cell lines).
Proliferation was analyzed after 6 days of treatment.
Grouping into pAKT responsive (red data points) and
nonresponsive (black data points) is described in (E).
The statistical significancewasdeterminedbyusing a t test
from the values achieved with 1 mg/ml trastuzumab.effects in HER2-positive breast cancer cell lines (Holbro et al.,
2003; Ram et al., 2000). We recently confirmed and extended
upon these observations by using a combination of RNA
silencing of HER receptor expression, a tumor model with induc-
ible HER3 knockdown, and the analysis of HER3 activation
status in HER2-positive breast cancer specimens (Lee-Hoeflich
et al., 2008). Based on these findings, we conclude that consti-
tutively active HER2 is dependent on HER3 for mediating its
effects, and that EGFR plays little or no role in driving the biology
of HER2-positive breast cancer.
Previously, we reported that pertuzumab binding to the extra-
cellular domain II of HER2 (Franklin et al., 2004) efficiently blocks
ligand-induced HER2/HER3 dimerization (Agus et al., 2002). In
contrast, trastuzumab binds to subdomain IV of HER2, which
results in the downregulation of PI3K/AKT signaling in tumor cells
that overexpress HER2 in the absence of ligands. An objective
of the present study was to examine the molecular basis for
trastuzumab’s effect on ligand-independent HER2/HER3/PI3K
signaling. In addition, we investigated GDC-0941, a potent and
selective PI3K inhibitor (Folkes et al., 2008) in model systems
that were sensitive and resistant to trastuzumab.430 Cancer Cell 15, 429–440, May 5, 2009 ª2009 Elsevier Inc.RESULTS
Trastuzumab Treatment of Tumors Inhibits the HER3/
PI3K/AKT Pathway In Vivo
To examine whether trastuzumab treatment results in dephos-
phorylation of HER3 and AKT in vivo, we treated mice harboring
established BT474-M1 tumors with 20 mg/kg trastuzumab for
48 hr. Tumor lysates were subjected to western blot (pHER3)
and ELISA (pAKT) analysis. Treatment with trastuzumab
(Figure 1A) significantly reduced the level of pHER3 (Tyr1289)
in the tumors (p = 0.0003, Dunnett’s test). Similarly, pAKT
(Ser473) was significantly reduced in trastuzumab-treated
tumors (p = 0.0072). Together, these data demonstrate that tras-
tuzumab treatment leads to inhibition of the HER3/PI3K/AKT
pathway in vivo.
Kinetics of HER3/PI3K/AKT Pathway Inhibition
by Trastuzumab
Although trastuzumab treatment is reported to decrease pHER3,
pAKT, andPI3Kactivity inHER2-amplified cells (Laneet al., 2000;
Yakes et al., 2002), the kinetics and contribution of this inhibition
Cancer Cell
Trastuzumab Disrupts the HER2/HER3/PI3K Complexto the antiproliferative effect are unclear. Yakes et al. (2002)
describe a robust initial increase in pHER3 after treatment for
1 hr with trastuzumab, followed by slow dephosphorylation after
12–24 hr. In contrast, we detect a rapid dephosphorylation of
HER3 (Tyr1289), visible already after 10 min of treatment with
trastuzumab in SKBR-3 and BT474-M1 cells. The degree of inhi-
bition plateaus at 80% after 60 min and was maintained for 6 hr
(Figure 1B; Figure S1A, available online). HER3 dephosphoryla-
tion was also reflected in loss of total phosphotyrosine and thus
is not specific for Tyr1289 (Figure S1B). Basal pHER3 is not
derived from ligand activation based on the following: (1) no
exogenous ligand is used in the experiments; (2) the cells do
not express HER3 ligands; (3) extended serum starvation does
not affect pHER3. Trastuzumab is also reported to decrease
HER2 phosphorylation (Lane et al., 2000). In contrast, we did
not detect inhibition of HER2 phosphorylation (Figure S1B).
Dephosphorylation of HER3 led to an immediate dissociation of
the p85 subunit of PI3K fromHER3 (Figure 1C). AKTdephosphor-
ylation (Ser473, Thr308) followed similar kinetics. Maximal inhibi-
tion was reached in 15–60min (Figure 1B; Figures S1A and S1B).
Dephosphorylation of the AKT substrate PRAS40 (Thr246) pro-
ceeded to a similar magnitude of inhibition and with parallel
kinetics (Figure 1B). Sergina et al. (2007) reported that small-
molecule EGFR tyrosine kinase inhibitors decrease HER3 and
AKTphosphorylation, but fail tomaintain dephosphorylation after
long-term incubation. In contrast, inhibition of HER3 and AKT
phosphorylation was sustained after 4 days of treatment with
trastuzumab (Figure 1D). In conclusion, trastuzumab causes an
immediate and potent inhibition of the HER3/PI3K/AKT pathway
that is maintained for at least 4 days. The kinetics andmagnitude
of pathway inhibition suggest that the effect has an important role
in the trastuzumab response.
Trastuzumab-Induced Growth Inhibition Correlates
with HER3/PI3K/AKT Pathway Inhibition In Vitro
We next analyzed whether the strong effect on the HER3/PI3K/
AKT pathway is predictive of antiproliferative responses in
high-HER2-expressing cell lines. We selected a set of breast
cancer cells known to overexpress HER2 (SKBR-3, BT474-M1,
AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, and
HCC-1954), a low-HER2-expressing breast cancer cell line
(MCF-7), and HER2-overexpressing lung, ovarian, and gastric
cancer cell lines (CALU-3, SKOV-3, and MKN-7, respectively).
Treatment of the cells with trastuzumab for 2 hr caused a strong
and dose-dependent (Figures 1E and 1F) decrease in AKT phos-
phorylation (60%–45%) in five HER2-overexpressing breast
cancer cell lines (SKBR-3, BT474-M1, AU-565, HCC-1419, and
ZR75-30). No AKT dephosphorylation was detected in other
cell lines (Figure 1E). All of the cell lines express detectable levels
of HER3 (Figure S2).
Inhibition of proliferation corresponded with the ability of tras-
tuzumab to inhibit pAKT. In SKBR-3 cells, trastuzumab treatment
inhibited both pAKT and proliferation by 50%–60%; in contrast,
no inhibition was detected in either pAKT or proliferation in
KPL-4 cells (Figure 1F). Cell lines were grouped as pAKT respon-
sive (>25% pAKT inhibition by 10 mg/ml trastuzumab) and pAKT
nonresponsive (<25%pAKT inhibition by 10 mg/ml trastuzumab).
Inhibition of proliferation strongly correlated with the ability oftrastuzumab to inhibit pAKT (p < 0.0001; t test at 1 mg/ml trastu-
zumab; Figure 1G).
All HER-family receptors are capable of activating the MEK/
ERK pathway (Hynes and Lane, 2005). Moreover, trastuzumab
was reported to inhibit ERK phosphorylation (Yakes et al.,
2002). We treated two trastuzumab-sensitive cell lines (SKBR-3,
BT474-M1) with the allosteric MEK inhibitor PD0325901 (Solit
et al., 2006). Although the MEK inhibition resulted in dephos-
phorylation of ERK, the inhibitor had a minimal effect on cell
proliferation (Figure S3), suggesting that the inhibitory effect of
trastuzumab on the MEK/ERK pathway is not sufficient for inhi-
bition of proliferation. This result is consistent with previous
similar experiments with BT474 xenografts (Solit et al., 2006).
In conclusion, the ability of trastuzumab to inhibit in vitro
proliferation correlates with HER3/PI3K/AKT pathway inhibition,
suggesting that the pathway inhibition is required for the antipro-
liferative effects and indicating that activating modifications
involving the PI3K pathway are a likely and important cause of
trastuzumab resistance.
The PI3K Inhibitor GDC-0941 Inhibits the Proliferation
of Both Trastuzumab-Sensitive and -Insensitive Cells
To further investigate whether the HER3/PI3K/AKT pathway is
controlling the proliferation and survival of HER2-amplified cells,
we treated all cell lines with GDC-0941. GDC-0941 inhibits
p110a, p110b, and p110d subunits of PI3Kwith strong selectivity
over other assayable kinases (Folkes et al., 2008). Treatment with
250 nM GDC-0941 for 2 hr resulted in 40%–85% inhibition of
pAKT in all cell lines tested (Figure 2A). No substantial difference
was observed in the degree of AKT dephosphorylation between
trastuzumab-sensitive and -insensitive cells after GDC-0941
treatment. The effect of GDC-0941 on cell proliferation/viability
was tested after 3 days of GDC-0941 treatment. Inhibition of
the PI3K/AKT pathway by GDC-0941 was reflected as a dose-
dependent reduction in cell proliferation/viability (Figure 2B).
GDC-0941 inhibited the growth of both trastuzumab-sensitive
and -insensitive cells (Figures 2B and 2C). The IC50 values for
GDC-0941 rangedbetween150and950nManddid not correlate
with trastuzumab sensitivity (p = 0.47; t test; Figure 2D). These
results confirm that PI3K/AKT pathway activity is directly linked
to the proliferation of HER2-overexpressing cells.
Trastuzumab Inhibits the Ligand-Independent
HER2/HER3 Interaction
Our recent studies confirmed that the complex of HER2 and
HER3 is a critical oncogenic unit in HER2-positive breast cancer
cell lines (Lee-Hoeflich et al., 2008). However, the initial effect of
trastuzumab on the HER2/HER3 complex is unclear. Previous
studies demonstrated that trastuzumabdoes not inducedownre-
gulation of HER2 (Austin et al., 2004). Furthermore, trastuzumab
does not reduce HER2 phosphorylation (Figure S1B). Our
previous report on the effect of trastuzumab on HER2/HER3
association focused on ligand-activated HER2/HER3 dimeriza-
tion (Agus et al., 2002). Using standard immunoprecipitation
methods (Agus et al., 2002) (Figure 3A, right panel), we were
initially unable to detect a direct HER2/HER3 interaction in the
absence of ligand stimulation. We hypothesized that heregulin
(HRG)/HER3/HER2complexes couldbemore stable or abundant
than the ligand-independent HER3/HER2 complexes that wereCancer Cell 15, 429–440, May 5, 2009 ª2009 Elsevier Inc. 431
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Trastuzumab Disrupts the HER2/HER3/PI3K Complexformed as a result of HER2 overexpression. It is likely that breast
cancers that overexpress HER2 may be activated in both a
ligand-independent and -dependent manner. To increase the
sensitivity of the analysis, we utilized a reversible chemical cross-
linkingprocedurewith 3,3-dithiobis[sulfosuccinimidylpropionate]
(DTSSP). This reagent crosslinks extracellular proteins through
amino groups. Even weakly interacting protein complexes
can then be coimmunoprecipitated. Protein complex compo-
Figure 2. The PI3K Inhibitor GDC-0941 Inhibits the Growth of Both
Trastuzumab-Sensitive and -Insensitive HER2-Amplified Cells
(A) Cells were treated with or without 250 nM GDC-0941 for 2 hr, lysed, and
subjected to pAKT ELISA (Ser473). Cell lines were grouped as trastuzumab-
sensitive (red columns) and -insensitive (black columns) according to prolifer-
ation inhibition by trastuzumab (Figure 1G). 25% inhibition was used as a cutoff
for the sensitivity.
(B) GDC-0941 dose response of trastuzumab-sensitive (SKBR-3) and -insen-
sitive (KPL-4) cells. pAKT (Ser473) was analyzed by ELISA after 2 hr of treat-
ment. Proliferation/viability was analyzed after 3 days of treatment.
(C) GDC-0941 dose response (see [A] for cell lines). Proliferation/viability was
analyzed after 3 days of treatment. Grouping to trastuzumab-sensitive (red)
and -insensitive cells (black) are described in (A). The statistical significance
was determined by using a t test from the values achieved with 500 nM
GDC-0941.
(D) Trastuzumab and GDC-0941 IC50 values (± standard error) from the prolif-
eration/viability assays (Figures 1G and [C]).432 Cancer Cell 15, 429–440, May 5, 2009 ª2009 Elsevier Inc.nents are identified by western blots after SDS-PAGE in reducing
conditions, which reverses the crosslinking. Ligand-independent
HER2/HER3complexeswere readily detected in SKBR-3 cells by
usingDTSSPcrosslinking (Figure 3A, left panel). TheHER2/HER3
interaction was significantly increased when cells were pre-
treated with the HER3 ligand HRG (Figure 3A). Consistent with
previous reports, pertuzumab efficiently inhibited ligand-induced
HER2/HER3dimerization,whereas trastuzumabhadonly aminor
effect (Figure 3A, right panel). Pertuzumab is a therapeutic
antibody thatbinds theextracellular domain II ofHER2andblocks
the association ofHER2withHER3whencells are stimulatedwith
HER3 ligand (Agus et al., 2002). Interestingly, in the absence of
HRG, the abilities of the antibodies to disrupt the ligand-indepen-
dent HER2/HER3 complex were reversed: the amount of HER3
associating with HER2 was clearly reduced when cells were
treated with trastuzumab (Figure 3A, left panel). Pertuzumab
caused a minor decrease in HER3 in complex with HER2
(Figure 3A, left panel).
Next, we performed a series of coimmunoprecipitation exper-
iments in the absence of the crosslinker. For this, we modified
the immunoprecipitation protocol by omitting the zwitterionic
detergent (CHAPS) from the lysis buffer, by increasing the
amount of lysate, and by utilizing amore sensitive chemilumines-
cent reagent. These modifications allowed us to detect ligand-
independent HER2/HER3 dimer in the absence of chemical
crosslinking. The kinetics of HER3 release from the HER2
complex corresponded with inhibition of the pHER3/pAKT
pathway after trastuzumab treatment, occurring 5–15 min after
trastuzumab addition (Figure 3B). Moreover, trastuzumab dis-
rupted the HER2/HER3 interaction in a dose-dependent manner
(Figure 3C), corresponding with the concentrations typically
required for AKT dephosphorylation (Figure 1F) and inhibition
of proliferation (Figure 1G).
We further hypothesized that if displacement of HER3 from
HER2 is essential for the antiproliferative activity of trastuzumab,
then interfering with the HER2/HER3 interaction should be
proportional to inhibiting cell proliferation. As predicted, trastu-
zumab inhibited pHER3, pAKT, and the proliferation of BT474-
M1 cells more efficiently than pertuzumab (Figures 3D–3F).
Together, these results demonstrate that trastuzumab treatment
disrupts ligand-independent HER2/HER3 association, which
results in a rapid decrease of HER3 phosphorylation and PI3K/
AKT pathway inactivation, ultimately leading to inhibition of cell
proliferation.
Trastuzumab and GDC-0941 Synergistically Inhibit
the PI3K/AKT Pathway and Cell Proliferation
Since both trastuzumab and GDC-0941 inhibit the PI3K/AKT
pathway, combining these inhibitors might result in additive or
synergistic effects on the proliferation of trastuzumab-sensitive
cell lines. Treatment of BT474-M1 with 10 mg/ml trastuzumab
caused an equal decrease in pAKT as 100 nM GDC-0941 treat-
ment (63% and 63% inhibition, respectively; Figure 4A). Addition
of trastuzumab to GDC-0941 caused a dose-dependent,
enhanced decrease in pAKT (Figure 4A). The addition of 10 mg/ml
trastuzumab resulted in a 67% reduction in pAKT compared to
50 nM GDC-0941 treatment alone.
Next, we evaluated whether the downstream AKT signaling
components were affected. The addition of trastuzumab to
Cancer Cell
Trastuzumab Disrupts the HER2/HER3/PI3K ComplexFigure 3. TrastuzumabDisrupts the Ligand-
Independent HER2/HER3 Interaction
(A) SKBR-3 cells were treated with 100 nM anti-
body (1 hr), followed by 0.5 nM heregulin (HRG,
12 min) when indicated. In the left panel, extracel-
lular proteins were crosslinked with DTSSP.
Lysates were immunoprecipitated by using anti-
HER2 antibody (7C2). SDS-PAGE in reducing
conditions reverses the crosslinking and allows
for quantitative analysis of coimmunoprecipitated
HER3 by western blot.
(B) BT474-M1 cells were treated with 10 mg/ml
trastuzumab. Lysates were immunoprecipitated
by using anti-HER2 antibody (7C2) and analyzed
for coimmunoprecipitating HER3 by western blot.
(C) Trastuzumab dose response (100 min) in
BT474-M1 cells was determined as in (B). HRG =
10 nM heregulin, 15 min.
(D and E) (D) BT474-M1 cells were treated with
10 mg/ml antibodies for 2 hr, and pHER3
(Tyr1289) was analyzed by western blot. (E) pAKT
(Ser473) was analyzed by ELISA. CTRL lanes
represent nontreated samples. Human IgG1 treat-
ment does not inhibit pHER3 or pAKT (data not
shown). HRG=10nMheregulin, 15min. The statis-
tical significance was determined by using Dun-
nett’s test.
(F) Proliferation of BT474-M1 was analyzed after
6 days of treatment with trastuzumab or pertuzu-
mab.GDC-0941 further decreased the phosphorylation of a direct AKT
substrate, PRAS40 (Thr246), and a distal substrate, phospho-S6
ribosomal protein (Ser235/236), demonstrating that trastuzumab
and GDC-0941 exhibit a pronounced combinatorial effect on
downstream AKT signaling (Figure 4B). Sergina et al. (2007)
recently reported a compensatory feedback from PI3K inhibition
that results in elevated pHER3. A similar compensatory effect on
pHER3 is seen when using GDC-0941 (Figure 4B). However,
addition of trastuzumab efficiently blocks this compensatory
effect (Figure 4B).
We next addressed whether enhanced PI3K/AKT pathway
inhibition results in decreased cell proliferation/viability. In the
absence of trastuzumab, the IC50 value for GDC-0941 in a 6-day
treatment of BT474-M1 was 296 nM (Figure 4C). The addition of
trastuzumab to GDC-0941 caused a dose-dependent decrease
in cell proliferation/viability. Addition of 10 mg/ml trastuzumab
resulted in a 64% decrease in the concentration of GDC-0941
that is required to reach its IC50 of 106 nM.A similar combinatorial
effect on pAKT and inhibition of proliferation was also observed
with SKBR-3 cells (data not shown), but not when the trastuzu-
mab-insensitive KPL-4 cells were treated (Figure S4). Prolifera-
tion data were analyzed by the established method of Chou
and Talalay (1984) by using CalcuSyn software. The resulting
combination index (C.I.) values were < 1 over most of the effect
range of the drugs (fractional effect 0.3–0.8), demonstrating
that the combination of trastuzumab and GDC-0941 inhibits
proliferation synergistically in BT474 and SKBR-3 cells
(Figure 4D). Together, these data show that combining trastuzu-
mab andGDC-0941 enhances the inhibitory effect on AKT and its
downstream targets, resulting in a synergistic effect on the prolif-
eration of trastuzumab-sensitive breast cancer cells. Our resultsalso demonstrate that trastuzumab blocks the compensatory
negative-feedback loop caused by GDC-0941 treatment
(Figure 4B), providing a plausible molecular mechanism that
promotes the synergistic effect observed with trastuzumab-
GDC-0941 combination treatment.
Combination of Trastuzumab and GDC-0941 Induces
Apoptosis of Breast Cancer Cells
To investigate the effect of the trastuzumab-GDC-0941combina-
tion on apoptosis, BT474-M1 cells were treated for 48 hr with
both inhibitors. Combining trastuzumab and GDC-0941
increased the accumulation of cleaved caspase-3 fragments,
indicating activation of this key effector caspase (Figure 4E).
Combining trastuzumab and GDC-0941 also resulted in an
increase in the cleaved PARP 89 kDa fragment, a known
response to caspase-3 activation (Figure 4E). The activity of cas-
pases 3 and 7 was also increased when trastuzumab was added
to GDC-0941 treatment (Figure 4F, left panel). Combining trastu-
zumab with 250 nM GDC-0941 increased caspase activity to a
level similar to that detected with a 4-fold higher dose (1000 nM)
of GDC-0941 alone. Importantly, this increase in caspase activity
was reflected in the apoptotic index of these cells. The addition of
10 mg/ml trastuzumab dramatically decreased the concentration
of GDC-0941 required to induce apoptosis (Figure 4F, middle
panel). A near equivalent level of apoptosis was detected when
cells were treated with 100 nM GDC-0941 and trastuzumab
than when treated with 1000 nM GDC-0941 alone. As expected,
the increase in apoptosis was reflected in a decrease in cell
viability after 48 hr (Figure 4F, right panel). A similar increase in
caspase activity and apoptosis was observed with SKBR-3 cells
(datanot shown). Together, thesedata show that thecombinationCancer Cell 15, 429–440, May 5, 2009 ª2009 Elsevier Inc. 433
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Trastuzumab Disrupts the HER2/HER3/PI3K ComplexFigure 4. GDC-0941 and Trastuzumab
Synergistically Inhibit Proliferation and
Induce Apoptosis
(A) BT474-M1 cells were treated with the indicated
GDC-0941concentrations and 0, 0.1, 1, or 10mg/ml
trastuzumab (black, red, green, and blue columns,
respectively). pAKT (Ser473; ±SD) was analyzed
by ELISA after 2 hr of treatment. The statistical
significance was determined by using Dunnett’s
test.
(B) BT474-M1 cells were treated with the indicated
GDC-0941 concentrations in the presence (+) or
absence () of 10 mg/ml trastuzumab for 4 hr.
pHER3 (Tyr1289), pAKT (Ser473), pPRAS-40
(Thr246), phospho-S6 ribosomal protein (pRP-
S6; Ser235/236), and tubulin were analyzed by
western blot.
(C) BT474-M1 cells were treated with the indicated
GDC-0941concentrations and 0, 0.1, 1, or 10mg/ml
trastuzumab (black, red, green, and blue
dots, respectively). Cell proliferation/viability was
analyzed and IC50 (± standard error) was deter-
mined after 6 days of treatment.
(D) The proliferation/viability of BT474 or SKBR-3
cells was analyzed after 3 days of treatment with
the drug combinations. Combination index (C.I.)
values were determined by using the method
of Chou and Talalay (1984) (CalcuSyn software)
for drug combinations with a fractional effect
between 0.2 and 0.9 (inhibiting 20%–90% of
proliferation/viability). C.I. values < 1 indicate drug
synergy.
(E) BT474-M1 cells were treated with the indicated
GDC-0941 concentrations in the presence (+)
or absence () of 10 mg/ml trastuzumab for 48 hr. pAKT (Ser473), cleaved caspase-3 (arrowheads depict 19 and 17 kDa fragments), cleaved PARP, and tubulin
were analyzed by western blot. Staurosporin (1 mM) was used as a positive control for apoptosis.
(F) BT474-M1 cells were treated with indicated GDC-0941 concentrations in the presence (red columns) or absence (black columns) of 10 mg/ml trastuzumab for
48 hr. The Caspase-Glo 3/7 assay, the Cell Death Detection ELISAplus assay, and the CellTiter-Glo Luminescent Cell Viability Assay were used to detect caspase
3/7 activity (left), apoptosis (middle), and cell viability (right). Bars represent mean ± SD. Staurosporin (1 mM) was used as positive control for apoptosis.of GDC-0941 with trastuzumab significantly lowers the GDC-
0941 concentration required for reaching the threshold of
caspase activation and apoptosis in trastuzumab-sensitive
breast cancer cells. Therefore, trastuzumab treatment sensitizes
HER2-amplified cells to PI3K inhibition and thus provides
an additional level of tumor specificity for the PI3K inhibitor
GDC-0941.
Activating PIK3CA Mutation Results in Independence
from HER2/HER3 Signaling and Trastuzumab
Resistance in MDA-MB-361.1 Cells
Mutations in PIK3CA, the gene encoding the catalytic p110a
subunit, can be found in 30% of breast tumors (Vogt et al.,
2007). PIK3CA mutations are clustered in ‘‘hot spots’’ of kinase
and helical domains, and 80% of the cancer-specific mutations
lead to a single amino acid substitution: E542K, E545K, or
H1047R (Vogt et al., 2007). These ‘‘hot spot mutations’’ increase
the activity of the kinase, can transform cells, and are oncogenic
in vivo. Activating PIK3CA mutations have also been suggested
to confer trastuzumab resistance (Berns et al., 2007). The MDA-
MB-361.1 breast cancer cell line harbors HER2 amplification
and an activating PIK3CA mutation (E545K). Trastuzumab
caused a similar decrease in pHER3 in MDA-MB-361.1 (Fig-
ure 5A) as was detected in trastuzumab-sensitive SKBR-3 cells434 Cancer Cell 15, 429–440, May 5, 2009 ª2009 Elsevier Inc.(Figure 1B). Dephosphorylation of HER3 also led to the dissocia-
tionof bothp85andp110subunits ofPI3K fromHER3 (Figure5B),
again similar to the trastuzumab-sensitive SKBR-3 (Figure 1C).
Despite the similar signaling changes seen upstream of PI3K
upon trastuzumab treatment, no decrease in pAKTwas detected
(Figure 5C), Accordingly, MDA-MB-361.1 cells also show resis-
tance to trastuzumab in cell proliferation assays (Figure 5D).
However, GDC-0941 efficiently inhibited AKT phosphorylation
(Figure 5E) and cell proliferation, as well as survival (IC50 of 443
nM; Figure 5F), confirming that MDA-MB-361.1 proliferation is
dependent on the PI3K/AKT pathway. In contrast, the prolifera-
tion ofMDA-MB-361.1 cells is not dependent on the HER2/HER3
oncogenic unit, as the cells retain proliferation capability when
treated with HER2 or HER3 siRNA (Figure 5G). Proliferation of
trastuzumab-sensitive cells, however, is abolished by siRNA
knockdown of either HER2 or HER3 (Figure 5H) (Lee-Hoeflich
et al., 2008). We also investigated the ability of GDC-0941 to
inhibit proliferation of other HER2-amplified cells that harbor
PIK3CA mutations. HCC-202, HCC-1954, and MDA-MB-453
cells express high levels of HER2 and have an activating PIK3CA
mutation (E545K, H1047R, and H1047R, respectively). All three
cell lineswith ahot spotPIK3CAmutationwere insensitive to tras-
tuzumab, but sensitive to GDC-0941 (IC50 values < 500 nM;
Figure S5). We returned to investigate the PIK3CA mutation
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mab-resistant cells carried the activating PIK3CA mutation or
were PTEN null (Figure S2). In contrast, no hot spot mutations
were detected in the trastuzumab-sensitive cell lines (Figure S2).
Together, these studies demonstrate that an activating hot
spot mutation in PIK3CA uncouples PI3K activity from the
HER2/HER3 oncogenic unit, which, in turn, renders these cell
lines insensitive to trastuzumab treatment. Furthermore, trastu-
zumab-resistant, HER2-amplified breast cancer cells with PI3K
mutations are sensitive to the PI3K inhibitor GDC-0941. It is likely
that GDC-0941 would be useful in the treatment of breast cancer
where activating PIK3CA mutations cause or contribute to tras-
tuzumab resistance.
HER2-Amplified Breast Cancer Cells that Are Resistant
to Trastuzumab Due to Loss of PTEN Are Sensitive
to GDC-0941
PTEN loss occurs commonly in breast tumors, can lead to acti-
vation of the PI3K/AKT pathway, and has been suggested to
cause trastuzumab resistance (Nagata et al., 2004). We
addressed whether GDC-0941 can overcome trastuzumab
resistance caused by PTEN loss. Transfection of SKBR-3 cells
with PTEN siRNA resulted in a 76% reduction of PTEN protein
and in a modest increase in pAKT (114% of CTRL siRNA treated
Figure 5. Activating PIK3CAHot Spot Muta-
tion Results in Independence from HER2/
HER3 Signaling and Trastuzumab Resis-
tance in MDA-MB-361.1 Cells
(A) MDA-MB-361.1 breast cancer cells, which
harbor HER2 amplification and PIK3CA E545K
mutation, were treated with 10 mg/ml trastuzumab
for 2 hr and analyzed for pHER3 (Tyr1289). CTRL
lanes represent nontreated samples. Human IgG1
treatment does not inhibit pHER3 (data not shown).
(B) The p85 and p110 subunits of PI3K were
detected from MDA-MB-361.1 HER3 immunopre-
cipitates by western blot after a 2 hr treatment
with 10 mg/ml trastuzumab, human IgG1 (CTRL),
or 250 nM GDC-0941.
(C–F) (C and E) MDA-MB-361.1 cells were treated
with the indicated doses of (C) trastuzumab or (E)
GDC-0941 for 2 hr, lysed, and subjected to pAKT
ELISA (Ser473). (D and F) Proliferation of MDA-
MB-361.1 was analyzed, and GDC-0941 IC50
(± standard error) was determined after (D) 6 days
of trastuzumabor (F)3daysofGCD-0941 treatment.
(G and H) (G) MDA-MB-361.1 and (H) BT474-M1
cellswere treatedwithpooledHER3,HER2, ornon-
targeting control (CTRL) siRNA for 48 hr. Prolifera-
tion (± SD) of cells was measured by using a
[3H]thymidine incorporation assay. Cytotoxic TOX
transfectioncontrol siRNAwasusedasan indicator
of successful transfection. Downregulation of
HER2 and HER3 in MDA-MB-361.1 cells after
siRNA treatment was detected by western blot.
by pAKT Ser473 ELISA) after 48 hr
(Figure 6A). Consistent with previous
reports (Nagata et al., 2004), knockdown
of PTEN resulted in trastuzumab resis-
tance (Figure 6A). Although PTEN loss
increased the GDC-0941 concentration required for inhibition
of proliferation, complete inhibition was achieved with 1 mM
concentration, demonstrating that GDC-0941 inhibits the growth
of SKBR-3 cells that were made resistant to trastuzumab due to
PTEN loss. A similar result was achieved with BT474-M1 cells
(data not shown). HCC-1569 is an HER2-amplified breast cancer
cell line that does not express detectable amounts of PTEN
(Figure S2). HCC-1569 cells are resistant to trastuzumab
(Figure 6B). Treatment of HCC-1569 with GDC-0941 resulted
in inhibition of AKT phosphorylation and inhibition of proliferation
(IC50 of 313 nM) (Figure 6B). Together, the results show that
GDC-0941 effectively inhibits both proliferation and the viability
of HER2-amplified breast cancer cells that are resistant to tras-
tuzumab due to PTEN loss, suggesting a clinical niche for this
PI3K inhibitor.
GDC-0941 Inhibits the Growth of HER2-Amplified,
Trastuzumab-Resistant Tumors with PIK3CA Mutation
In Vivo
MDA-MB-361.1 cells were implanted in themammary fat pads of
nudemice. After tumor establishment, themicewere treatedwith
3 mg/kg weekly doses of trastuzumab or vehicle. After the third
trastuzumab dose, it was apparent that the MDA-MB-361.1
tumors did not respond to trastuzumab in vivo (Figure 7A). NoCancer Cell 15, 429–440, May 5, 2009 ª2009 Elsevier Inc. 435
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Trastuzumab Due to PTEN Loss Are Sensi-
tive to GDC-0941
(A) SKBR-3 cells were transfected with PTEN
(black columns) or nontargeting control (gray
columns) siRNA. After 24 hr, cells were treated
with the indicated concentrations of trastuzumab
or GDC-0941 for 48 hr, and proliferation (± SD)
was measured by a [3H]thymidine incorporation
assay. PTEN and pAKT (Ser473) levels after siRNA
treatment were detected by western blot.
(B) The trastuzumab and GDC-0941 dose
response of HCC-1569 breast cancer cells. Cell
proliferation was analyzed, and IC50 (±standard
error) was determined after 6 days of trastuzumab
or 3 days of GDC-0941 treatment. pAKT (Ser473)
was analyzed by ELISA after 2 hr of treatment.responses were observed even with a higher 30 mg/kg weekly
trastuzumab dose, which causes complete responses in trastu-
zumab-sensitive models (data not shown). At day 17 of the tras-
tuzumab treatment, both vehicle and trastuzumab groups were
randomly divided in half. Daily oral administration of GDC-0941
at 150mg/kgwas delivered to half of themice, whereas the other
half received the formulation buffer of the PI3K inhibitor. Addition
of GDC-0941 to the dose regimen stopped the growth of MDA-
MB-361.1 tumors, whereas tumors continued to grow in vehicle-
treated mice (Figure 7A). Response to treatment was monitored
as time to tumor progression (the time when tumor volume
reached twice the volume on day 17). GDC-0941 significantly
delayed the tumor progression both alone and in combination
with trastuzumab (p = 0.0049, p = 0.0018, respectively). The
in vivo combination of trastuzumab and GDC-0941 did not result
in a significant benefit over the single-agent GDC-0941 regimen.
Increased PARP cleavage was detected in tumors treated for
7–24 hr with 100–150 mg/kg PI3K inhibitor, suggesting that
GDC-0941 induces apoptosis in tumors (data not shown). In
summary, these results demonstrate that GDC-0941 is effective
in treating HER2-amplified, trastuzumab-resistant mammary
tumors harboring PIK3CAmutations in vivo.
The combination of Trastuzumab and GDC-0941
Is Efficient in Treatment of Trastuzumab-Sensitive
Tumors In Vivo
To address whether the trastuzumab and GDC-0941 combina-
tion would result in more efficient inhibition of tumor growth
than the single agents, we treated BT474-M1 tumor xenografts
with trastuzumab (20 mg/kg, iv, 23/wk 3 3), GDC-0941
(100mg/kg, po, qd3 21), or a combination of the agents. As pre-
dicted by the in vitro studies, the combination of inhibitors was
more efficient in inhibition of the BT474-M1 tumors than either
of the single agents (Figure 7B).
DISCUSSION
Clinical observations indicate that not all patients benefit from
trastuzumab-based therapies. Moreover, a subset of patients
progress after an initial response. The nature of both innate
and acquired resistance is an area of active research in both436 Cancer Cell 15, 429–440, May 5, 2009 ª2009 Elsevier Inc.the laboratory and the clinic. In the present work, we show that
the antiproliferative activity of trastuzumab is directly linked to
its ability to disrupt the constitutive, ligand-independent HER2/
HER3/PI3K signaling complex that forms as a result of HER2
Figure 7. GDC-0941 Is Highly Efficacious Both in Treating Trastuzu-
mab-Resistant Tumors and in Combination with Trastuzumab in
Treating Trastuzumab-Sensitive Tumors In Vivo
(A) Pre-established MDA-MB-361.1 tumor xenografts were treated with
weekly doses of trastuzumab (intraperitoneal; 3 mg/kg; red dotted line) or
vehicle (black dotted line). After 17 days, mice were randomized, and half of
the groups received additional GDC-0941 (daily oral gavage; 150 mg/kg3 25;
black and red solid lines). The remaining half was administered with vehicle
(dotted red and black lines). Data are presented asmean tumor volume ± SEM.
(B) Pre-established BT474-M1 tumor xenografts were treated with vehicle
(black dotted line), trastuzumab (intravenous; 20mg/kg; 23/wk3 3; red dotted
line), GDC-0941 (daily oral gavage; 100 mg/kg3 21; black line), or a combina-
tion of the agents (red line). Data are presented as mean tumor volume ± SEM.
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generate trastuzumab resistance and that trastuzumab-resistant
cell lines commonly harbor activating ‘‘hot spot’’ PI3K mutations
or are PTEN null. Additionally, we demonstrate that the selective
PI3K inhibitor GDC-0941 significantly inhibits proliferation of
both trastuzumab-sensitive and -insensitive cell lines.
Several studies have noted that trastuzumab treatment leads
to a downregulation of AKT signaling (Lane et al., 2000; Yakes
et al., 2002). We recently extended this observation by showing
that HER2 and HER3 form the major oncogenic unit in HER2-
positive breast cancer (Lee-Hoeflich et al., 2008). However, the
molecular details concerning the mechanism by which trastuzu-
mab disrupts constitutive AKT signaling remains elusive. In the
present work, we provide direct evidence for the ability of trastu-
zumab to disrupt the oncogenic ligand-independent HER2/
HER3/PI3K complex, resulting in rapid inhibition of AKT signaling
and cell proliferation. Our results clarify several previously
unclear areas of signaling changes caused by trastuzumab.
We establish that inhibition of HER3 phosphorylation and the
subsequent dissociation of p85, which, in turn, leads to downre-
gulation of AKT signaling, is an immediate effect after trastuzu-
mab treatment and correlates with the disruption of HER2/
HER3 complexes. Previous studies have reported much slower
kinetics for the inhibition of HER3/AKT signaling (Yakes et al.,
2002), which was attributed to downregulation of HER2 from
the cell surface (Hudziak et al., 1989). However, subsequent
studies clearly indicate that trastuzumab treatment does not
alter cell surface HER2 levels (Austin et al., 2004; Hommelgaard
et al., 2004). We also fail to observe any transient increase in
HER3 or HER2 phosphorylation after trastuzumab treatment
that was reported in previous studies (Sarup et al., 1991; Yakes
et al., 2002). Additionally, we do not observe the trastuzumab-
mediated HER2 dephosphorylation that had been suggested
as the mechanism of action for trastuzumab (Lane et al., 2000;
Nagata et al., 2004; Sarup et al., 1991). We conclude from our
results that the inhibition of PI3K/AKT signaling by trastuzumab
is caused by disruption of ligand-independent HER2/HER3
association, which, in turn, is critical for the cytostatic activity
of trastuzumab. Our model does not require trastuzumab-medi-
ated activation of PTEN through src for trastuzumab to mediate
its antisignaling activity (Nagata et al., 2004). However, some of
the previously described mechanisms of action, including the
ability to inhibit HER2 shedding (Molina et al., 2001), may still
be valid in some context.
Previously, we reported that pertuzumab, a therapeutic anti-
body that binds extracellular domain II of HER2 (Franklin et al.,
2004), functions by blocking the association of HER2 with
ligand-occupied HER3 (Agus et al., 2002). In contrast, trastuzu-
mab, which binds to subdomain IV of HER2, had little effect on
ligand-mediated HER2/HER3 association (Agus et al., 2002). In
the present study, we demonstrate that HER2/HER3 complexes
can be isolated from cell lines that overexpress HER2 without
stimulating receptor dimerization by ligand. In the absence
of HRG, trastuzumab is superior to pertuzumab in disrupting
constitutive HER2/HER3 complexes. These findings raise the
possibility that when HER2 is overexpressed and in the absence
of ligand, the HER2/HER3 interaction is fundamentally different
from the canonical ligand-induced, receptor-mediated dimeriza-
tion model proposed by structural studies. The findings furtherimply that the domain II-domain II interface may not mediate
interactions in the ligand-independent receptor complex. The
ability to detect HER2 in association with HER3 confirms and
extends the notion that the oncogenic unit in HER2-positive
breast cancer is a complex of HER2 and HER3 that signals
constitutively to PI3K and AKT (Lee-Hoeflich et al., 2008). One
hypothesis, supported by studies of Landgraf and colleagues,
is that HER2/HER3 complexes exist in the membrane in micro-
domains, and that subsequent binding of monoclonal antibodies
to HER2 accelerates the partitioning of HER2 away from these
microdomains, thereby limiting access to HER3 (Kani et al.,
2005). Trastuzumab, which binds near the transmembrane
region in domain IV, appears to be more effective in accelerating
this partitioning event. Experiments to test this hypothesis are
currently ongoing.
It is clear that the oncogenic potential of HER2 in HER2-ampli-
fied breast cancer is primarily, if not solely, mediated by its ability
to inappropriately activate HER3 and the PI3K pathway (sche-
matically depicted in Figure 8A) (Lee-Hoeflich et al., 2008). In
the current study, we demonstrate that trastuzumab can disrupt
the ligand-independent HER2/HER3/PI3K complex in both tras-
tuzumab-sensitive (Figure 8A) and -insensitive cells (Figure 8B).
In the latter case, the breast cancer cell lines that harbor alter-
ations in the PI3K pathway remain sensitive to GDC-0941,
a highly specific and effective PI3K inhibitor (Figure 8B). Several
properties that are critical for therapeutic agents differentiate
GDC-0941 from previously tested PI3K inhibitors, including
wortmannin and LY294002 (Bain et al., 2007; Hennessy et al.,
2005; Nagata et al., 2004). First, GDC-0941 is highly selective
for class IA PI3K (Folkes et al., 2008). Importantly, it also displays
favorable pharmacokinetic and toxicological properties that
enable therapeutic use in vivo (Folkes et al., 2008). Given this
advantageous profile, GDC-0941 is currently undergoing early
clinical testing for treatment of various advanced malignancies.
A recent publication showed that a dual PI3K/mTOR inhibitor is
able to inhibit growth of tumors with PIK3CAmutation. However,
the study did not demonstrate whether PI3K/mTOR inhibitor
overcomes trastuzumab resistance in vivo (Serra et al., 2008).
In trastuzumab-sensitive cells, trastuzumab and GDC-0941
inhibit proliferation and cell viability synergistically. Recently, it
was reported that PI3K inhibition leads to a compensatory
increase in HER3 phosphorylation, which was linked to AKT-
mediated negative-feedback signaling (Sergina et al., 2007). In
the present report, we observe that treatment of HER2-amplified
breast cancer cells with GDC-0941 also results in negative feed-
back that is manifested by an increase in HER3 phosphorylation.
When trastuzumab is given with GDC-0941, the feedback loop
fails due to the disruption of the HER2/HER3 complex. As
a consequence of feedback loop failure, trastuzumab and
GDC-0941 are observed to be synergistic in cells that are sensi-
tive to trastuzumab’s antiproliferative effects.
Several clinical implications can be drawn from our studies.
First, PI3K inhibitors, suchasGDC-0941, could beused in combi-
nation with trastuzumab-based therapies, and, based on our
current study, it is anticipated that the combination will be highly
effective. Second, GDC-0941 may be effective in patients who
progress on trastuzumab or lapatinib therapy. Third, patients
whose tumors contain HER2 gene amplification and also harbor
PI3K pathway alterations are candidates for GDC-0941 therapyCancer Cell 15, 429–440, May 5, 2009 ª2009 Elsevier Inc. 437
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regimens. Our mechanistic studies predict that these patients
would also be refractory to HER2 tyrosine kinase inhibitors,
such as lapatinib, in agreement with a previous report (Eichhorn
et al., 2008). Fourth, our studies suggest that it is imperative to
clinically validatewhether patientswho initially respond to trastu-
zumab or lapatinib therapy and then progress acquire PI3K
pathway alterations. Only detailed molecular analysis of longitu-
dinal biopsy specimens from the same patient’s tumor under-
going these therapies will provide definitive data in support of
this hypothesis.
In summary, this study characterizes a mechanism of action
for trastuzumab whereby trastuzumab disrupts basal, ligand-
independent HER2/HER3 interactions in HER2-amplified cells.
The disruption of the constitutively active receptor complex
Figure 8. Schematic Representation of the Mechanism of Action for
Trastuzumab andHowPI3K Activation Leads to Trastuzumab Resis-
tance
(A) Amplification of HER2 leads to ligand-independent HER2/HER3 interaction
and HER3 phosphorylation. Phosphorylated HER3 activates the PI3K pathway
promoting cell survival andproliferation. Trastuzumabdisrupts the ligand-inde-
pendent HER2/HER3 interaction, leading to rapid HER3 dephosphorylation
and inhibition of the PI3K/AKT pathway, thereby inhibiting cell proliferation.
(B) PI3K mutation or PTEN loss results in HER2/HER3-independent signaling
and trastuzumab resistance. However, a novel class IA PI3K small-molecule
inhibitor, GDC-0941, inhibits both wild-type and mutant PI3K and overcomes
trastuzumab resistance generated by PI3K mutations or PTEN loss.
(C) Ligand-induced HER2/HER3 dimerization can occur in both HER2-ampli-
fied and nonamplified cells. Pertuzumab is efficient in preventing ligand-
induced HER2/HER3 dimerization.438 Cancer Cell 15, 429–440, May 5, 2009 ª2009 Elsevier Inc.leads to rapid inhibition of the HER3/PI3K/AKT pathway and
cell proliferation. We also show that the PI3K inhibitor GDC-
0941 is highly efficacious both in combination with trastuzumab
and in the treatment of trastuzumab-resistant cells and tumors.
EXPERIMENTAL PROCEDURES
Cell Lines
Breast cancer cell lines BT474-M1, BT474-EEI, and MDA-MB-361.1 are
in vivo-passaged subclones of BT474 and MDA-MB-361 cells (American
Type Culture Collection [ATCC], Manassas, VA). The generation of BT474 sub-
clones has been previously described (Clynes et al., 2000; Lewis Phillips et al.,
2008). For in vivo passaging of MDA-MB-361, the parental cell lines were
grown as xenografts, and the tumors were regrafted once. A new cell line
(MDA-MB-361.1) was generated from the in vivo-passaged tumors and was
used in all in vitro and in vivo experiments. KPL-4 breast cancer cells were
obtained from J. Kurebayashi (Kurebayashi et al., 1999), and MKN-7 gastric
carcinoma cells were obtained from Mitsubishi Corp. (Tokyo, Japan). All other
cell lines were obtained from ATCC or Deutsche Sammlung vonMikroorganis-
men und Zellkulturen GmbH (DSMZ, Braunschweig, Germany). Cell lines were
maintained in high-glucose DMEM:Ham’s F-12 (50:50) supplemented with
10% FBS and 2 mM L-glutamine.
Analysis of HER3/PI3K/AKT Pathway Activation
Cells were lysed with nondenaturing lysis buffer including 1% Triton (Cell
Signaling Technology [CST] Cat#9803; Danvers, MA). The activation of the
HER3/PI3K/AKT pathway was detected by using antibodies against pHER3
(Tyr1289; CST), phospho-S6 ribosomal protein (Ser235/236; CST), and
pPRAS40 (Thr246; Invitrogen/Biosource, Carlsbad, CA). AKT phosphorylation
was detected by western blot or ELISA detecting phosphorylated Ser473
(CST). The association of PI3K with HER3 was analyzed by immunoprecipita-
tion with agarose-conjugated HER3 antibody (sc-285; Santa Cruz, Santa Cruz,
CA), followed by detection with p85 (Millipore/Upstate, Billerica, MA) or p110
antibody (clone EP383Y; Epitomics, Burlingame, CA).
For analysis of pHER3 and pAKT in vivo, tumor-bearing Rag2mice (Taconic,
Germantown, NY) were treated with 20 mg/kg (iv) trastuzumab or control anti-
body for 48 hr. Tumors were snap frozen and homogenized in cell lysis buffer
(CST; Cat#9803). Ratios of pHER3 to total HER3 and pAKT to total AKT were
determined by western blot and ELISA, respectively.
Receptor Crosslinking and HER2 Coimmunoprecipitation
SKBR-3 cells were incubated in growth medium with 10% fetal bovine serum
and 10 mM HEPES (pH 7.2) for 1 hr at 37C with the indicated treatment anti-
body. The cells were washed twice with ice-cold 50 mM HEPES (pH 7.2),
150 mMNaCl (HEPES/NaCl buffer) and were incubated with 2 mM 3,30-dithio-
bis[sulfosuccinimidylpropionate] (DTSSP) dissolved in HEPES/NaCl buffer for
60 min at 4C. After the incubation with DTSSP, the cells were washed three
times with ice-cold 25 mM Tris (pH 7.1), 150 mM NaCl and lysed in 1.0% v/v
Triton X-100, 1.0% w/v CHAPS in RPMI with 10 mM HEPES (pH 7.2) supple-
mentedwith protease andphosphatase inhibitors. ForHER2 immunoprecipita-
tion, N-terminal anti-HER2 antibody 7C2 (Genentech; binds to extracellular
domain I of HER2) was conjugated to Ultralink biosupport (Pierce, Rockford,
IL) by incubation in 100 mM HEPES (pH 8.2), 150 mM NaCl buffer in 4C over-
night. The conjugated beads were washed, and free amines were blocked with
3M ethanolamine (pH 9). In Figures 3B and 3C, cells were lysed with nondena-
turing lysis buffer (1% Triton, 20 mM Tris-HCl [pH 7.5], 150 mMNaCl, protease
and phosphatase inhibitors; CST; Cat#9803). Lysate (1 [Figure 3A] to 3 mg
[Figures 3B and 3C]) was used for overnight immunoprecipitation in 4C with
20 ml 7C2 beads. After immunoprecipitation, 7C2 beads were washed twice
with lysis buffer. SDS-sample buffer containing anadditional 50mMdithiothrei-
tol was added to each precipitate, and the samples were boiled for 4 min.
Coimmunoprecipitating HER3 was analyzed by western blot with C-terminal
HER3 antibody (sc-285; Santa Cruz).
siRNA
siRNA was introduced into BT474-M1 cells (1.73 104/well of 96-well plate) by
reverse transfection by using Lipofectamine-2000 (Invitrogen) as previously
Cancer Cell
Trastuzumab Disrupts the HER2/HER3/PI3K Complexdescribed (Lee-Hoeflich et al., 2008). For transfection of MDA-MB-361.1,
43 103 cells were grown in 96-well plates and transfected with Lipofectamine
on the following day. Sets of four pooled siRNA oligos (50 nM) were used for
PTEN, HER3, and nontargeting siRNA (siGENOME, siCONTROL; Dharmacon,
Lafayette, CO). HER2 oligos (pool of four) have been previously described
(Lee-Hoeflich et al., 2008). TOX transfection control siRNA (Dharmacon) was
used as an indicator of successful transfection. Treatments were started
24 hr after transfection, and the effect of 48 hr of treatment on cell proliferation
and protein expression was determined.
Cell Proliferation/Viability
Proliferation/viability of cells was detected by using the CellTiter-Glo Lumines-
cent Cell Viability Assay (Promega, Madison, WI). For the assay, 5 3 103 cells
were plated on 96-well plates and incubated overnight for cell attachment.
Cells were treated for 6 days with antibodies or 3 days with PI3K inhibitor
before analysis. After transfection with siRNA, proliferation was detected by
a [3H]thymidine incorporation assay after 48 hr of treatment as previously
described (Lee-Hoeflich et al., 2008). All measurements were performed in
triplicate.
Determination of Drug Synergy
Cells were seeded at a density of 2.53 103 (BT474) or 1.53 103 (SKBR-3) cells
per well of a 384-well plate. Concentration ranges were chosen to span the
complete dose-response range of both drugs. All treatments were performed
in quadruplicate. Cell proliferation/viability was determined after 3 days by
using the Luminescent Cell Viability Assay (Promega). Multiple drug effect
analysis was performed by using CalcuSyn software (Biosoft, Cambridge,
United Kingdom), which quantitatively describes the interaction between
two or more drugs (Chou and Talalay, 1984). This method assigns combination
index (C.I.) values to each drug combination and defines drug synergy when
a C.I. value is less than 1 or drug antagonism when a C.I. value is greater
than 1. C.I. values were determined at 7–9 unique data points for each cell
line, which corresponded to 20%–90% of cell growth inhibition relative to
control.
Caspase Activation and Apoptosis
For detection of caspase activity and apoptosis, 1.53 104 cells were plated on
96-well plates and incubated overnight before 48 hr treatments and the Cas-
pase-Glo 3/7 assay (Promega) or Cell Death Detection ELISAplus assay (Roche;
measures cytoplasmic histone-associated DNA fragments indicative of
apoptosis). Cleaved caspase-3 (Asp175; 5A1) and cleaved PARP (Asp214)
were detected with antibodies that do not recognize the respective full-length
proteins (CST).
In Vivo Drug Efficacy
For MDA-MB-361.1 xenograft studies, NCR nudemice (Taconic) were supple-
mented with subcutaneous estrogen pellets (0.36 mg, 60-day release; Innova-
tive Research of America). After 3 days, 5 million MDA-MB-361.1 cells were
injected into the mammary fat pad in a 1:1 HBSS:matrigel suspension (BD
matrigel; BD Biosystems, San Jose, CA). When tumor volumes reached
200–300 mm3, mice were randomly grouped for the treatment cohorts. For
BT474-M1 xenograft studies, 1 mm3 tumor fragments were implanted subcu-
taneously in the flank of the mice (Fox Chase SCID, C.B-17/IcrHsd-Prkdcscid,
Harlan). When tumor volumes reached an average of 125 mm3, mice were
randomized for treatment groups. Dosing and drug are described in the figure
legends. Tumor volumes were calculated with the formula: (mm3) = (L3W2)3
0.5. All animal procedures followed protocols approved by the Institutional
Animal Care and Use Committee (IACUC).
Statistical Analysis
All statistical analysis was performed by using JMP 7.0 software (SAS Institute
Inc., Cary, NC).
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